|
| Status |
Public on Feb 27, 2025 |
| Title |
Comprehensive Analysis of Relapsed-Refractory Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents |
| Organism |
Homo sapiens |
| Experiment type |
Genome variation profiling by SNP array
|
| Summary |
Outcome of paediatric B-cell Non-Hodgkin Lymphoma (B-NHL) has significantly improved in the last decades due to risk adapted strategies and the addition of immunotherapy, (survival >90%). However, limited progress has been achieved in relapsed patients, mostly Burkitt lymphoma (<30%). Validation of prognostic biomarkers to identify candidates to novel therapies is imperative. This retrospective study reports on clinical and therapeutic data of 46 children and adolescents with relapsed B-NHL, including integrative molecular data of 16 (35%) cases. TP53 alterations were identified in 10 (60%) patients which were associated with worse outcome. Our data support the focus on TP53 as a potential biomarker.
|
| |
|
| Overall design |
Outcome of pediatric B-cell Non-Hodgkin Lymphoma (B-NHL) has significantly improved in the last decades due to risk adapted strategies and the addition of immunotherapy, (survival >90%). However, limited progress has been achieved in relapsed patients, mostly Burkitt lymphoma (<30%). Validation of prognostic biomarkers to identify candidates to novel therapies is imperative. This retrospective study reports on clinical and therapeutic data of 45 children and adolescents with relapsed B-NHL, including integrative molecular data of 17 (37%) cases.
CNAs were examined in 23 samples from 17 patients (from 8 patients available at diagnosis, 5 patients with paired samples, and 5 patients with only relapse samples). using Oncoscan (22 samples) or Cytoscan (1 sample) platforms (ThermoFisher Scientific, Waltham, MA, USA) according to standard protocols. Gains and losses and regions of CN neutral loss of heterozygosity (CNN-LOH) were evaluated using Nexus Biodiscovery v9.0 software (Biodiscovery, Hawthorne, CA, USA).
CNAs were identified in all investigated samples. Median CNAs was 5.5 at diagnosis (range 0–19) and 7 at relapse (range 1–88). No differences were observed in terms of genomic complexity between diagnosis and relapse (mean 6.9 vs 16 CNA/case, p-value 0.47), nor between our R/R series and B-NHL series not enriched in relapse cases. We investigated the CN profile of the 17 patients with available material. Recurrent CNAs (>20%) included 1q21.1-q25.3, and 13q31.3 gains, and 4p16.3, 4q34.3-q35.3, 9q21.3-q22.32, 17p13.1-p11.2/TP53, and Yp11.31-q11.23 losses. CNN-LOH of 17p13.3-p11.2 including TP53 were also recurrent, affecting 29% of the patients.
|
| |
|
| Contributor(s) |
Mato S, Salaverria I |
| Citation(s) |
- Mato S, Carità L, Colmenero A, Andrés M et al. Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents. Br J Haematol 2025 Feb 26. PMID: 40011029
|
| |
| Submission date |
Jun 06, 2024 |
| Last update date |
Feb 28, 2025 |
| Contact name |
Itziar Salaverria |
| E-mail(s) |
isalaver@clinic.cat
|
| Organization name |
Hospital Clínic
|
| Street address |
Rossello 153
|
| City |
Barcelona |
| ZIP/Postal code |
08036 |
| Country |
Spain |
| |
|
| Platforms (2) |
| GPL16131 |
[CytoScanHD_Array] Affymetrix CytoScan HD Array |
| GPL18602 |
[OncoScan] Affymetrix OncoScan FFPE Assay |
|
|
